Aligos Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $62.94 million
- Book Value:
- Revenue TTM:
- $10.74 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aligos Therapeutics Inc had its IPO on 2020-10-16 under the ticker symbol ALGS.
The company operates in the Healthcare sector and Biotechnology industry. Aligos Therapeutics Inc has a staff strength of 89 employees.
Shares of Aligos Therapeutics Inc opened at $1.19 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $1.12 - $1.21, and closed at $1.19.
This is a 0% increase from the previous day's closing price.
A total volume of 124,878 shares were traded at the close of the day’s session.
In the last one week, shares of Aligos Therapeutics Inc have increased by +7.21%.
Aligos Therapeutics Inc's Key Ratios
Aligos Therapeutics Inc has a market cap of $62.94 million, indicating a price to book ratio of 0.3509 and a price to sales ratio of 3.7883.
In the last 12-months Aligos Therapeutics Inc’s revenue was $10.74 million with a gross profit of $-99794000 and an EBITDA of $-110334000. The EBITDA ratio measures Aligos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aligos Therapeutics Inc’s operating margin was -1051% while its return on assets stood at -33.02% with a return of equity of -66%.
In Q3, Aligos Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 167.1%.
Aligos Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aligos Therapeutics Inc’s profitability.
Aligos Therapeutics Inc stock is trading at a EV to sales ratio of 69.4811 and a EV to EBITDA ratio of 0.7928. Its price to sales ratio in the trailing 12-months stood at 3.7883.
Aligos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $164.07 million
- Total Liabilities
- $30.54 million
- Operating Cash Flow
- $32.48 million
- Capital Expenditure
- Dividend Payout Ratio
Aligos Therapeutics Inc ended 2023 with $164.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $164.07 million while shareholder equity stood at $122.01 million.
Aligos Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $30.54 million in other current liabilities, 4000.00 in common stock, $-377232000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $86.44 million and cash and short-term investments were $142.30 million. The company’s total short-term debt was $3,207,000 while long-term debt stood at $0.
Aligos Therapeutics Inc’s total current assets stands at $150.09 million while long-term investments were $0.00 and short-term investments were $55.86 million. Its net receivables were $0 compared to accounts payable of $2.93 million and inventory worth $0.
In 2023, Aligos Therapeutics Inc's operating cash flow was $32.48 million while its capital expenditure stood at $3000.
Comparatively, Aligos Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aligos Therapeutics Inc stock is currently trading at $1.19 per share. It touched a 52-week high of $2.99 and a 52-week low of $2.99. Analysts tracking the stock have a 12-month average target price of $3.64.
Its 50-day moving average was $1.08 and 200-day moving average was $1.22 The short ratio stood at 1.55 indicating a short percent outstanding of 0%.
Around 1534.7% of the company’s stock are held by insiders while 6198.4% are held by institutions.
Frequently Asked Questions About Aligos Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.